Lipedema Clinical Trial
— LipidExOfficial title:
The Effects of Endurance Training in Women With Lipedema
NCT number | NCT05488977 |
Other study ID # | 461077 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | July 1, 2022 |
Est. completion date | December 31, 2026 |
Lipedema is a fat disorder causing accumulation of subcutaneous adipose tissue particularly in arms and legs, and predominantly affects women. Lipedema likely contributes to an array of other pathologies, including obesity, inflammatory bowel disease, and neurological disorders. Lipedema tissue is often very painful and can severely impair mobility. The condition can also increase the incidence of depression, anxiety, or eating disorders. There seems to be a general impression that lipedema tissue is difficult to reduce by diet, exercise, or bariatric surgery. However, only a few studies have actually explored the effects of exercise training on lipedema. Despite the lack of knowledge, the existing guidelines for lipidemia treatment promote a healthy lifestyle with individually adjusted weight control measures, including physical activity. In general, exercise is known to have an important effect on adipose tissue. Excess adipose tissue causes macrophage infiltration into the adipose tissue leading to continuous low systemic inflammation. This would suggest that there is a systemic inflammatory response in lipedema patients. Increasing IL-6 levels with exercise can decrease the level of proinflammatory TNFalpha synthesized from adipocytes and therefore lead to an anti-inflammatory effect by increasing IL-10 and IL-1ra levels. IL-6 also stimulates fat oxidation by increasing lipolysis. For these reasons, adding an appropriate exercise program to standard treatment might provide additional benefits for lipedema patients. The investigators aim to determine the therapeutic potential of high-intensity interval training (HIIT) on pain, quality of life, body composition, cardiorespiratory fitness and circulating biomarkers in women with lipedema.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | December 31, 2026 |
Est. primary completion date | December 31, 2026 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - can meet for supervised exercise training in Trondheim. Exclusion Criteria: - eating disorders and/or orthopedic limitations for exercise training |
Country | Name | City | State |
---|---|---|---|
Norway | Institute for Circulation and Medical Imaging, NTNU | Trondheim |
Lead Sponsor | Collaborator |
---|---|
Norwegian University of Science and Technology | St. Olavs Hospital |
Norway,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Visual analog scale (VAS) | Visual analog scale (VAS), measured by means of a 0-100 mm, for pain will be used to collect data on pain. VAS has been used in the social and behavioral sciences to measure a variety of subjective phenomena. A VAS is a straight line, whose end anchors indicate the extreme boundaries of the sensation, feeling, or responses to be measured. For example, a VAS to measure pain can be labeled "no pain" on one end and "pain as bad as it could possibly be" on the other end. Subjects respond to the VAS by placing a mark through the line at a position which best represents their current perception of a given phenomenon between the labeled extremes. Although a VAS may be horizontal or vertical and of any length deemed appropriate, its most common form is a 100 mm horizontal line. The VAS is scored by measuring the distance, usually in millimeters, from one end of the scale to the subject's mark on the line. | Change from baseline to 8 weeks | |
Secondary | LYMQOL (Lymphoedema Quality of Life) legs | Self-reported questionnaire reporting quality of life adapted to lipedema patients.
This questionnaire has been designed and validated for patients with chronic oedema/ lymphoedema of one or both legs to measure quality of life. The patients will tick the box that best describes how they feel about each of the questions.The questionaire includes 22 main questions. The patient may tick one of the following; "Not at all", "A little", "Quite a bit" or "A lot". The last question includes a scale. The title of the scale is "Overall, how would you rate your quality of life at present?". The minimum value is 0 and mean Poor, whereas the maximum value is 10 and means Excellent. |
Change from baseline to 8 weeks | |
Secondary | Brief Pain Inventory | Self-reported questionnaire reporting pain. The Brief Pain Inventory is a validated, widely used, self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions. The title of the scale is pain. The BPI scale defines pain as follows:
Worst Pain Score: 1 - 4 = Mild Pain. Worst Pain Score: 5 - 6 = Moderate Pain. Worst Pain Score: 7 - 10 = Severe Pain. |
Change from baseline to 8 weeks | |
Secondary | Short Form Health Survey-36 (SF-36) | Self-reported questionnaire reporting quality of life. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. | Change from baseline to 8 weeks | |
Secondary | Glucose | Serum levels of glucose | Change from baseline to 8 weeks | |
Secondary | HbA1C | Serum levels of HbA1C | Change from baseline to 8 weeks | |
Secondary | Triglycerides | Serum levels of triglycerides | Change from baseline to 8 weeks | |
Secondary | HDL-cholesterol | Serum levels of HDL-cholesterol | Change from baseline to 8 weeks | |
Secondary | Total cholesterol | Serum levels of total cholesterol | Change from baseline to 8 weeks | |
Secondary | Ferritin | Serum levels of ferritin | Change from baseline to 8 weeks | |
Secondary | hs-CRP | Serum levels of hs-CRP | Change from baseline to 8 weeks | |
Secondary | Interleukin | Serum levels of interleukin | Change from baseline to 8 weeks | |
Secondary | PF4/CXCL4 | Serum levels of PF4/CXCL4 | Change from baseline to 8 weeks | |
Secondary | TNFalpha | Serum levels of TNFalpha | Change from baseline to 8 weeks | |
Secondary | Protein levels in blood | Aprox. 200 proteins will be quantified (mmol/l) in blood by nuclear magnetic resonance. | Change from baseline to 8 weeks | |
Secondary | Systolic blood pressure | Systolic blood pressure | Change from baseline to 8 weeks | |
Secondary | Diastolic blood pressure | Diastolic blood pressure | Change from baseline to 8 weeks | |
Secondary | Body weight | Body weight based on InBody 720 | Change from baseline to 8 weeks | |
Secondary | Muscle mass | Total muscle mass and in different parts of the body based on InBody 720 | Change from baseline to 8 weeks | |
Secondary | Fat percentage | Total fat percentage and in different parts of the body based on InBody 720 | Change from baseline to 8 weeks | |
Secondary | Resting metabolism | Whole body resting metabolism based on InBody 720 | Change from baseline to 8 weeks | |
Secondary | Maximal oxygen uptake | VO2max will be measured during uphill treadmill walking or running (Woodway PPS 55 Med, Munich, Germany), using ergospirometry (Jaeger, Oxycon pro, Hoechberg, Germany / Meta Max II, Cortex, Leipzig, Germany) | Change from baseline to 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04492046 -
Complex Decongestive Applications in Patients With Lipedema
|
||
Completed |
NCT04643392 -
Physiotherapy Applications in Upper Extremity Lipedema
|
||
Recruiting |
NCT05464927 -
Visualizing Vascular Mechanisms of Lipedema
|
||
Completed |
NCT02907411 -
Quadrivas Therapy® to Reduce Lipedema Subcutaneous Adipose Tissue (QUADRIVAS)
|
N/A | |
Completed |
NCT06238791 -
Plantar Pressure Analysis and Foot Biomechanics in Lipedema and Chronic Venous Disease
|
||
Completed |
NCT03758651 -
Williams Syndrome Strength, Hormones, Activity & Adiposity, DNA Programming, Eating Study
|
||
Completed |
NCT03710798 -
Effect of an Low Carbon High Fat Diet on Pain- and Quality of Life in Patients With Lipedema
|
N/A | |
Not yet recruiting |
NCT04166084 -
Trunk Stabilization Exercises at Lipoedema Patients
|
N/A | |
Recruiting |
NCT05628948 -
Vascular Lab Resource (VLR) Biorepository
|
||
Not yet recruiting |
NCT05944796 -
Diathermy Effectiveness in Reducing Subcutaneous Adipose Tissue Affected by Lipedema
|
N/A | |
Completed |
NCT05616962 -
Collected Data of Medical Food, Vasculera or Diosmiplex, in Clinic Patients 20 to 70 Years Old Diagnosed With Lipedema
|
N/A | |
Active, not recruiting |
NCT04632810 -
Effect of Ketosis on Pain and Quality of Life in Patients With Lipedema
|
N/A | |
Recruiting |
NCT05284266 -
The National Lipedema Study
|
N/A | |
Active, not recruiting |
NCT06338059 -
Relationship Between Vitamin D and Vitamin B12 Levels and Neuropathic Pain in Lipedema
|
||
Completed |
NCT04076891 -
Treatment of Women With Lipedema Involving Substantial Fat Above the Knee or of Women and Men With Nodular Dercum's Disease
|
Phase 2 | |
Completed |
NCT03492840 -
Treatment of Women With Lipedema Involving Substantial Fat Knee of Women and Men With Nodular Dercum's Disease
|
Phase 2 | |
Recruiting |
NCT02838277 -
Insight Into Subcutaneous Adipose Tissue Disorders
|
N/A | |
Completed |
NCT05966779 -
Physical Therapy in Lipedema Surgery
|
||
Completed |
NCT04213989 -
Intermittent Pneumatic Compression in Women With Lipo-lymphedema (Lipedema With Swelling)
|
N/A | |
Enrolling by invitation |
NCT00833599 -
Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic Disorders
|